98%
921
2 minutes
20
Endoscopic submucosal dissection is used to treat early gastric neoplasms. Compared with other endoscopic procedures, it requires higher doses of opioids, leading to adverse events during monitored anesthesia care. We investigated the correlations between clinicopathological characteristics and intraprocedural opioid requirements in patients who underwent endoscopic submucosal dissection under monitored anesthesia care. The medical records of patients who underwent endoscopic submucosal dissection under monitored anesthesia care were retrospectively reviewed. The dependent variable was the total dose of fentanyl administered during the dissection, while independent variables were patient demographics, the American Society of Anesthesiologists physical status classification, preoperative vital sign data, and the pathological characteristics of the neoplasm. Correlations between variables were examined using multiple regression analysis. : The study included 743 patients. The median total fentanyl dose was 100 mcg. Younger age (coefficient -1.37; 95% confidence interval [CI] -1.78 to -0.95), male sex (16.12; 95% CI 6.99-25.24), baseline diastolic blood pressure (0.44; 95% CI 0.04-0.85), neoplasm length (1.63; 95% CI 0.90-2.36), and fibrosis (28.59; 95% CI 17.77-39.42) were positively correlated with the total fentanyl dose. Total fentanyl dose was higher in the differentiated (16.37; 95% CI 6.40-26.35) and undifferentiated cancers group (32.53; 95% CI 16.95-48.11) than in the dysplasia group; no significant differences were observed among the others. The mid-anterior wall (22.69; 95% CI 1.25-44.13), mid-posterior wall (29.65; 95% CI 14.39-44.91), mid-greater curvature (28.77; 95% CI 8.56-48.98), and upper groups (30.06; 95% CI 5.01-55.12) had higher total fentanyl doses than the lower group, whereas doses did not significantly differ for the mid-lesser curvature group. : We identified variables that influenced opioid requirements during monitored anesthesia care for endoscopic submucosal dissection. These may help predict the needed opioid doses and identify factors affecting intraprocedural opioid requirements.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11172858 | PMC |
http://dx.doi.org/10.3390/jcm13113119 | DOI Listing |
Khirurgiia (Mosk)
September 2025
National Medical Research Center of Oncology, Rostov-on-Don, Russia.
Objective: To study the results of treatment of cancer in tubular villous adenomas.
Material And Methods: A retrospective analysis included 51 patients with cTis-T1N0M0 between 02.2019 and 09.
Surg Case Rep
September 2025
Department of Pathology, Self-Defense Forces Central Hospital, Tokyo, Japan.
Introduction: Solitary fibrous tumor (SFT) is a rare mesenchymal neoplasm that most commonly originates in the pleura but can also occur at extrapleural sites, including the abdominal cavity. Among these, primary SFT of the stomach is exceptionally rare. Due to overlapping clinical, endoscopic, and radiologic characteristics, distinguishing SFT from gastrointestinal stromal tumor (GIST) can be particularly challenging.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Department of Endoscopy Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Surg Endosc
September 2025
Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Background: Current guidelines recommend that rectal neuroendocrine tumors (NETs) smaller than 10 mm can be treated by endoscopic resection, whereas tumors larger than 20 mm should be treated by surgical resection. However, the optimal treatment of 10-20 mm rectal NETs remains controversial. We aimed to evaluate the efficacy of endoscopic submucosal dissection (ESD) for 10-20 mm rectal NETs based on resection margin status.
View Article and Find Full Text PDFInt J Surg
September 2025
Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Background And Aims: A scoring model was proposed to support endoscopic decision-making for cardial submucosal tumors (SMTs). The aim of this study is to perform a multicenter validation of the clinical scoring model and to introduce a new clinical classification system for cardial SMTs.
Methods: A multicenter analysis of endoscopic decision-making for cardial submucosal tumors (SMTs) was conducted.